Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560
Recruiting
Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +36 locations
Conditions: Mitral Stenosis, Mitral Valve Insufficiency
Register for Updates
National Fully Remote Use of IpsiHand Device in Hemiparetic Stroke
NCT05965713
Recruiting
The goal of this study is to define the efficacy of fully remote home-based BCI therapy in chronic hemiparetic subcortical stroke patients. A randomized controlled study using the integrated remote BCI system will be tested against standard exercise therapy to determine the efficacy of motor improvement in chronic stroke patients with an upper extremity hemiparesis. Specifically, the integrated BCI system will include 1) the remote screening and motor assessment system for the upper extremity an... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: Neurolutions, Saint Louis, Missouri
Conditions: Stroke, Hemiparesis, Spasticity as Sequela of Stroke, Brain Computer Interface
Register for Updates
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: Clinical Study Site, Lancaster, California +138 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries
NCT06379425
Recruiting
This is a double-arm randomized control trial evaluating the impact of preoperative opioid-free analgesia on time to trial of void in ambulatory urogynecologic surgeries. The investigators hypothesize that receipt of acetaminophen, celecoxib and gabapentin preoperatively versus acetaminophen alone will reduce the time to trial of void in patients undergoing same-day minor urogynecologic procedures.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/19/2025
Locations: Northwell Health South Shore Surgery Center, Bay Shore, New York
Conditions: Pain, Postoperative, Postoperative Pain, Acute
Register for Updates
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
NCT06541262
Recruiting
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/19/2025
Locations: Arnold Palmer Hospital for Children, Orlando, Florida +4 locations
Conditions: Neuroblastoma Recurrent, Ewing's Sarcoma Recurrent, Osteosarcoma Recurrent, Rhabdomyosarcoma Recurrent, Liposarcoma Recurrent
Register for Updates
The Effects of Endotracheal Suctioning on Pain and Serum Markers
NCT06692400
Recruiting
The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Loma Linda University Medical Center Troesh Medical Campus, Loma Linda, California
Conditions: Intensive Care Unit ICU, Intubation, Critical Illness, Mechanical Ventilation, Pain Measurement, Pain, Procedural, Oxidative Stress, Hypoxia, Biomarkers / Blood, Adult, Uric Acid, Sepsis, COVID, Influenza, Pneumonia
Register for Updates
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798
Recruiting
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Research Site, Phoenix, Arizona +118 locations
Conditions: Delayed Graft Function, DGF, Kidney Transplant
Register for Updates
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
NCT03661307
Recruiting
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed). Quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
Register for Updates
External Device for Erectile Dysfunction (3D-Erect)
NCT04624126
Recruiting
The aim of this clinical trial is to test the safety and feasibility of a non-invasive 3D-printed external penile device to achieve successful and satisfactory sexual intercourse in men with erectile dysfunction (ED).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Stanford Health Care, Stanford Hospital, Stanford, California
Conditions: Erectile Dysfunction, Impotentia Erigendi
Register for Updates
Genetic Collection Protocol
NCT05272319
Recruiting
This study involves the one-time collection of whole blood or saliva samples for the extraction and storage of DNA for use in ongoing and future ChiLDReN studies.
Gender:
ALL
Ages:
Between 24 hours and 25 years
Trial Updated:
05/19/2025
Locations: Children's Hospital of Los Angeles, Los Angeles, California +12 locations
Conditions: Liver Diseases
Register for Updates
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
05/19/2025
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +83 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
NCT06016179
Recruiting
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
05/19/2025
Locations: Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Malignant Pleural Effusion, Malignant Ascites
Register for Updates